Skip to main content

Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy

Breast Cancer Research and Treatment volume 172, pages 239–240 (2018)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Poggio F, Bruzzone M, Ceppi M et al. (2018) Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. https://doi.org/10.1093/annonc/mdy127

    Article  PubMed  Google Scholar 

  2. Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767

    CAS  Article  Google Scholar 

  3. Bareche Y, Venet D, Ignatiadis M et al. (2018) Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol 29(4):895–902

    CAS  Article  Google Scholar 

  4. Telli ML, Timms KM, Reid J et al. (2016) Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 22(15):3764–73

    CAS  Article  Google Scholar 

  5. Telli ML, Metzger O, Timms KM et al. (2018) Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin ± veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. J Clin Oncol 36:519 (suppl; abstr 519)

    Article  Google Scholar 

Download references

Author information

Affiliations

  1. Medical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

    Mattia Rediti

  2. Academic Unit of Medical Oncology, Department of Internal Medicine, School of Medicine, Policlinico Hospital San Martino-IST, University of Genoa, Largo R. Benzi 10, 16132, Genoa, Italy

    Carlo Messina

Authors
  1. Mattia Rediti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlo Messina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Messina.

Ethics declarations

Conflict of interest

All authors declare no conflicts of interest.

Ethical approval

This study does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

It was unnecessary given this letter does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rediti, M., Messina, C. Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy. Breast Cancer Res Treat 172, 239–240 (2018). https://doi.org/10.1007/s10549-018-4885-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-018-4885-9